Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis.
Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis.
复制标题
DOI：
10.3389/fcvm.2021.700233
复制
发表时间：
2021
影响因子：
3.6
通讯作者：
Zhang Y
中科院分区：
文献类型：
--
作者：
Abudukeremu A;Huang C;Li H;Sun R;Liu X;Wu X;Xie X;Huang J;Zhang J;Bao J;Zhang Y
背景资料：虽然药物升高HDL-C水平对心血管终点无益处，但高密度脂蛋白/载脂蛋白A1（HDL/apoA-1）替代治疗对动脉粥样硬化的影响仍存在争议。目前的荟萃分析分析分析了HDL/apoA-1替代疗法对人类和小鼠动脉粥样硬化病变的影响。方法：检索PubMed、科克伦图书馆、Web of Science和EMBASE数据库，截止日期为2020年6月6日。使用Review Manager（RevMan，版本5.3）评估人体研究的方法学质量。使用阶梯列表评估小鼠研究的方法学质量。使用STATA（版本14.0）进行所有统计分析。结果：纳入15项随机对照人体试验和17项动物研究。汇总结果显示，在急性冠状动脉综合征（ACS）患者（N = 754）中，使用HDL/apoA-1替代疗法并未显著降低动脉粥样硬化体积百分比（p = 0.766）或总动脉粥样硬化体积（p = 0.510）。然而，HDL/apoA-1替代治疗与最终病变面积百分比、最终病变面积和病变面积变化显著相关。（SMD，−1.75; 95%CI：−2.21~-1.29，p = 0.000; SMD，−0.78; 95%CI：−1.18~-0.38，p = 0.000; SMD：−2.06; 95%CI，−3.92~-0.2，p = 0.03）。结论：HDL/apoA-1替代疗法是安全的，但不能显著改善人类动脉粥样硬化体积。动物实验结果表明，HDL/apoA-1替代疗法可减少病变面积。需要进一步的研究来调查和解释人类和动物之间HDL/apoA-1替代疗法疗效的差异。试验注册号：人体汇总分析：PROSPERO，CRD 42020210772。前瞻性登记。
Background: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA-1 replacement therapies on atherosclerotic lesions both in humans and mice. Methods: The PubMed, Cochrane Library, Web of Science, and EMBASE databases were searched through June 6, 2020. The methodological quality of the human studies was assessed using Review Manager (RevMan, version 5.3.). The methodological quality of the mouse studies was assessed using a stair list. STATA (version 14.0) was used to perform all statistical analyses. Results: Fifteen randomized controlled human trials and 17 animal studies were included. The pooled results showed that HDL/apoA-1 replacement therapy use did not significantly decrease the percent atheroma volume (p = 0.766) or total atheroma volume (p = 0.510) in acute coronary syndrome (ACS) patients (N = 754). However, HDL/apoA-1 replacement therapies were significantly associated with the final percent lesion area, final lesion area, and changes in lesion area (SMD, −1.75; 95% CI: −2.21~-1.29, p = 0.000; SMD, −0.78; 95% CI: −1.18~-0.38, p = 0.000; SMD: −2.06; 95% CI, −3.92~-0.2, p = 0.03, respectively) in mice. Conclusions: HDL/apoA-1 replacement therapies are safe but do not significantly improve arterial atheroma volume in humans. The results in animals suggest that HDL/apoA-1 replacement therapies decrease the lesion area. Additional studies are needed to investigate and explain the differences in HDL/apoA-1 replacement therapy efficacies between humans and animals. Trial registration number: Human pooled analysis: PROSPERO, CRD42020210772. prospectively registered.
登录
查看更多内容
影响因子：
6.5
作者：
Bielicki, John K.;Zhang, Haiyan;Azhar, Salman
通讯作者：
Azhar, Salman
影响因子：
37.8
作者：
Michael Gibson C;Korjian S;Tricoci P;Daaboul Y;Yee M;Jain P;Alexander JH;Steg PG;Lincoff AM;Kastelein JJ;Mehran R;D'Andrea DM;Deckelbaum LI;Merkely B;Zarebinski M;Ophuis TO;Harrington RA
通讯作者：
Harrington RA
影响因子：
4.8
作者：
Gibson, C. Michael;Kerneis, Mathieu;Merkely, Bela
通讯作者：
Merkely, Bela
影响因子：
5.3
作者：
de Souza, Juliana A.;Vindis, Cecile;Kontush, Anatol
通讯作者：
Kontush, Anatol
DOI：
10.1124/jpet.110.167890
发表时间：
2010-08-10
影响因子：
3.5
作者：
Amar, Marcelo J. A.;D'Souza, Wilissa;Remaley, Alan T.
通讯作者：
Remaley, Alan T.